Can Coherence's Brain Implant Fight Cancer? Inside the Startup's $45M Seed Round

Coherence, a neurotechnology company building a brain implant to fight cancer, has raised a $45 million seed round. Peter Thiel's Founders Fund and OpenAI's Startup Fund joined the round alongside Lux Capital, 8VC and Neuralink's head neurosurgeon, among others, according to Inc.

The company was co-founded in 2022 by Ben Woodington and Dr. Elise Jenkins.

What Coherence Is Building

Coherence's device, called SOMA, is a button-sized implant that monitors the electrical signals coming from a tumor and can deliver electrical stimulation designed to slow its growth. The implant pairs with a coin-sized, removable over-ear wearable and an app that gives patients and clinicians real-time data, symptom tracking and therapy history.

Its first target is glioblastoma, the most aggressive form of brain cancer. In early safety testing, implants were placed in consenting patients for 30 minutes during other surgeries and then removed. The company's preclinical work in mice uses the device's data to predict how tumors will grow.

Where the Money Goes

The founders wrote in a Substack post cited by Inc. that the company is "pushing ahead to our first chronic human trial in glioblastoma, seeking FDA breakthrough device designation." The funding will also expand preclinical research into pancreatic cancer and other indications, and grow the team.

Why It Matters Now

So can an implant really fight cancer? The idea is less far-fetched than it sounds. Tumors are electrically active tissue, and researchers have spent years studying how electric fields affect cancer cell division. A wearable therapy that uses alternating electric fields is already approved for glioblastoma. Coherence's twist is putting the sensor and stimulator at the tumor itself, which could allow continuous monitoring and a therapy that adjusts to what the tumor is doing in real time.

That would matter for a disease with few good options. Glioblastoma comes back in most patients after surgery, radiation and chemotherapy, and doctors typically rely on periodic MRI scans to see whether it is returning. A device that reads tumor activity continuously could flag changes far earlier, giving care teams time to act.

The investor list is notable too. A $45 million seed is unusually large for a medical device company, and the presence of OpenAI's fund and a Neuralink surgeon reflects how brain-computer interface technology is moving from research labs toward clinical products. The founders framed the stakes broadly, writing that "everything about how cancer is managed both through treatment and remission is set to evolve."

The expansion into pancreatic cancer hints at the larger ambition. If electrical monitoring and stimulation work in the brain, the same platform could, in theory, be adapted to other solid tumors that are hard to track and harder to treat.

The hard part is still ahead. A chronic human trial will be the first real test of whether SOMA is safe to leave in place and whether its stimulation measurably slows tumors. Until that data arrives, Coherence is a well-funded hypothesis, but one with backers willing to bet it can change how cancer is managed.

Source

Inc. — "OpenAI and Peter Thiel Just Joined a $45 Million Bet on a Brain Implant That Fights Cancer"